Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers

被引：0
|
作者：
Laurence Gabriel
Michel Tod
Sylvain Goutelle
机构：
[1] Hôpital Gériatrique Pierre Garraud,Service Pharmaceutique
[2] Hospices Civils de Lyon,ISPB
[3] Université de Lyon,Faculté de Pharmacie de Lyon
[4] Université Lyon 1,Service Pharmaceutique, Hôpital de la Croix
[5] Hospices Civils de Lyon,Rousse
[6] Université Lyon 1,UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive
来源：
Clinical Pharmacokinetics | 2016年 / 55卷
关键词：
Melatonin; Fluvoxamine; Substrate Drug; Vemurafenib; Enoxacin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：977 / 990
页数：13
相关论文
共 50 条
  • [1] Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers
    Gabriel, Laurence
    Tod, Michel
    Goutelle, Sylvain
    [J]. CLINICAL PHARMACOKINETICS, 2016, 55 (08) : 977 - 990
  • [2] Determination of drug interactions with CYP1A2
    Volak, LP
    Meissen, JK
    Zlokarnik, G
    [J]. DRUG METABOLISM REVIEWS, 2003, 35 : 90 - 90
  • [3] Quantitative prediction of CYP1A2-mediated drug interactions
    Gabriel, L.
    Tod, M.
    Goutelle, S.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 12 - 12
  • [4] Quantitative prediction of oral drug interactions caused by CYP3A4 inhibition for an extended panel of substrates and inhibitors
    Loue, C.
    Tod, M.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 21 - 21
  • [5] Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: Implications for in vitro prediction of drug interactions
    Karjalainen, Marjo J.
    Neuvonen, Pertti J.
    Backman, Janne T.
    [J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (12) : 2091 - 2096
  • [6] Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors
    Kulanthaivel, Palaniappan
    Mahadevan, Daruka
    Turner, P. Kellie
    Royalty, Jane
    Ng, Wee Teck
    Yi, Ping
    Rehmel, Jessica
    Cassidy, Kenneth
    Chappell, Jill
    [J]. CANCER RESEARCH, 2016, 76
  • [7] A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)
    Lorenzo Villa-Zapata
    Ainhoa Gómez-Lumbreras
    John Horn
    Malinda S. Tan
    Richard D. Boyce
    Daniel C. Malone
    [J]. Drug Safety, 2022, 45 : 863 - 871
  • [8] Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung
    Wei, C
    Caccavale, RJ
    Weyand, EH
    Chen, S
    Iba, MM
    [J]. CANCER LETTERS, 2002, 178 (01) : 25 - 36
  • [9] Quantitative prediction of CYP2D6-mediated drug interactions
    Tod, M.
    Goutelle, S.
    Clabel-Grabit, F.
    Nicolas, G.
    Charpiat, B.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 1 - 1
  • [10] A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)
    Villa-Zapata, Lorenzo
    Gomez-Lumbreras, Ainhoa
    Horn, John
    Tan, Malinda S.
    Boyce, Richard D.
    Malone, Daniel C.
    [J]. DRUG SAFETY, 2022, 45 (08) : 863 - 871
12345